Eric D Miller
Overview
Explore the profile of Eric D Miller including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
69
Citations
2288
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Miller E, Klamer B, Cloyd J, Pawlik T, Williams T, Hitchcock K, et al.
Clin Colorectal Cancer
. 2024 Feb;
23(2):160-173.
PMID: 38365567
Background: A survey of medical oncologists (MOs), radiation oncologists (ROs), and surgical oncologists (SOs) who are experts in the management of patients with metastatic colorectal cancer (mCRC) was conducted to...
12.
Hitchcock K, Miller E, Shi Q, Dixon J, Gholami S, White S, et al.
BMC Cancer
. 2024 Feb;
24(1):201.
PMID: 38350888
Background: For patients with liver-confined metastatic colorectal cancer (mCRC), local therapy of isolated metastases has been associated with long-term progression-free and overall survival (OS). However, for patients with more advanced...
13.
Hitchcock K, Miller E, Shi Q, Dixon J, Gholami S, White S, et al.
Res Sq
. 2024 Jan;
PMID: 38196590
Background: For patients with liver-confined metastatic colorectal cancer (mCRC), local therapy of isolated metastases has been associated with long-term progression-free and overall survival (OS). However, for patients with more advanced...
14.
Romesser P, Capdevila J, Garcia-Carbonero R, Philip T, Fernandez Martos C, Tuli R, et al.
Clin Cancer Res
. 2023 Dec;
30(4):695-702.
PMID: 38051750
Purpose: Peposertib-an orally administered DNA-dependent protein kinase inhibitor-has shown potent radiosensitization in preclinical models. This dose-escalation study (NCT03770689) aimed to define the maximum tolerated dose (MTD) and recommended phase II...
15.
Ritter A, Miller E
Int J Radiat Oncol Biol Phys
. 2023 Oct;
117(4):786.
PMID: 37838448
No abstract available.
16.
Miller E, Wu T, McKinley G, Slivnick J, Guha A, Mo X, et al.
Int J Radiat Oncol Biol Phys
. 2023 Aug;
118(1):124-136.
PMID: 37574171
Purpose: Radiation therapy (RT) associates with long-term cardiotoxicity. In preclinical models, RT exposure induces early cardiotoxic arrhythmias including atrial fibrillation (AF). Yet, whether this occurs in patients is unknown. Methods...
17.
Makary M, Bozer J, Miller E, Diaz D, Rikabi A
Acad Radiol
. 2023 Aug;
31(5):1828-1835.
PMID: 37537129
Rationale And Objectives: To examine the clinical outcomes of yttrium-90 (Y90) transarterial radioembolization (TARE) for primary hepatocellular carcinoma (HCC) through the evaluation of a 5-year institutional experience. Materials And Methods:...
18.
Facer B, Cloyd J, Manne A, Pitter K, Diaz D, Bazan J, et al.
Cancers (Basel)
. 2023 Jul;
15(14).
PMID: 37509388
Surgical resection is the standard of care for ampullary adenocarcinoma (AC). Many patients are ineligible due to comorbidities/advanced disease. Evidence for the optimal non-operative management of localized AC is lacking....
19.
Benson A, Venook A, Al-Hawary M, Azad N, Chen Y, Ciombor K, et al.
J Natl Compr Canc Netw
. 2023 Jun;
21(6):653-677.
PMID: 37308125
This discussion summarizes the NCCN Clinical Practice Guidelines for managing squamous cell anal carcinoma, which represents the most common histologic form of the disease. A multidisciplinary approach including physicians from...
20.
Ritter A, Miller E
Surg Oncol Clin N Am
. 2023 May;
32(3):537-552.
PMID: 37182991
Despite improvements in definitive therapy, many patients with gastrointestinal malignancies experience local recurrences or have unresectable disease making subsequent management often challenging and morbid. Although higher doses of radiation may...